Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose therapy for breast cancer

L Vahdat1, K Antman

  • 1Columbia University College of Physicians and Surgeons, New York, NY, USA.

Blood Reviews
|September 1, 1995
PubMed
Summary

High-dose chemotherapy, supported by growth factors or stem cells, offers improved treatment strategies for advanced breast cancer. Ongoing supportive care advancements minimize treatment toxicities, enhancing patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

Kinetics of amoxicillin and clavulanate degradation alone and in combination in aqueous solution under frozen conditions.

International journal of pharmaceutics·2007
Same author

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.

Annals of oncology : official journal of the European Society for Medical Oncology·2006

Area of Science:

  • Oncology
  • Hematology
  • Clinical Therapeutics

Background:

  • Breast cancer in young women often presents with advanced disease and poor prognosis.
  • High lymph node involvement correlates with unfavorable outcomes.
  • Need for novel treatment strategies is critical.

Purpose of the Study:

  • To review dose intensification strategies for breast cancer.
  • To evaluate the role of hematopoietic growth factors and stem cells in high-dose chemotherapy.
  • To summarize existing evidence on high-dose chemotherapy in Stages II-IV breast cancer.

Main Methods:

  • Review of published studies on high-dose chemotherapy.
  • Inclusion of randomized comparisons with conventional therapy.
  • Discussion of supportive care improvements.

Main Results:

  • Dose intensification is supported by preclinical and clinical data.
  • Published studies of high-dose chemotherapy in Stages II-IV breast cancer are summarized.
  • Randomized comparisons indicate potential benefits.

Conclusions:

  • High-dose chemotherapy, with supportive care, is a viable strategy for advanced breast cancer.
  • Hematopoietic support enhances the feasibility of dose intensification.
  • Advances in supportive care reduce treatment-related toxicities, improving safety and efficacy.

Related Experiment Videos